NRIX
Closed
Nurix Therapeutics inc
11.71
+0.32 (+2.81%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 11.39
Day's Range: 11.34 - 11.975
Send
sign up or login to leave a comment!
When Written:
9.32
Nurix Therapeutics Inc. is a biopharmaceutical company that focuses on discovering and developing small molecule drugs that target the ubiquitin proteasome system (UPS). The UPS is a cellular pathway that regulates protein degradation and plays a critical role in many cellular processes, including cell cycle control, DNA repair, and immune response. The company was founded in 2015 and is headquartered in San Francisco, California. Nurix's technology platform enables the discovery of small molecule drugs that modulate the activity of E3 ubiquitin ligases, enzymes that are responsible for the recognition and tagging of proteins for degradation by the UPS. The company's lead program is focused on developing therapies for cancer and immune disorders. Nurix has partnerships with several pharmaceutical companies, including Gilead Sciences, Sanofi, and Vertex Pharmaceuticals.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








